MediWound to Report First Quarter Financial Results and Host a Conference Call and Webcast on May 17, 2022
MediWound Ltd. (Nasdaq: MDWD) will announce its first-quarter financial results on May 17, 2022. The release will be followed by a conference call at 8:30 AM ET for management to discuss these results and provide corporate updates. MediWound specializes in bio-therapeutic solutions for tissue repair, notably its product NexoBrid for thermal burns, which has received support from BARDA. The company is also developing EscharEx for chronic wounds and MW005 for non-melanoma skin cancers. The webcast will be accessible for 90 days following the call.
- NexoBrid is marketed in the EU and at registration-stage in the U.S., showing potential for revenue growth.
- EscharEx demonstrated safety and efficacy in Phase 2 studies, indicating positive clinical prospects.
- None.
YAVNE, Israel, May 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the first quarter ended March 31, 2022 on Tuesday, May 17, 2022.
Following the release, MediWound's management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide corporate updates and answer questions. Dial-in and call details are as follows:
| Conference Call & Webcast Details | |
| Toll-Free: | 877-602-7189 |
| Israel: | 1-809-315-362 |
| International: | 678-894-3057 |
| Conference ID: | 1297705 |
| Webcast: | Click HERE |
To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay for 90 days in the Investors section of the MediWound website.
About MediWound Ltd.
MediWound is a biopharmaceutical company that develops, manufactures, and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Our strategy leverages our enzymatic technology platform, focused on next-generation bioactive therapies for burn care, wound care and tissue repair.
NexoBrid®, our commercial orphan biological product for non-surgical eschar removal of deep-partial and full-thickness thermal burns, is a bromelain-based biological product containing a sterile mixture of proteolytic enzymes that selectively removes burn eschar within four hours without harming surrounding viable tissue. NexoBrid is currently marketed in the European Union and other international markets and is at registration-stage in the U.S. NexoBrid is supported by the U.S. Biomedical Advanced Research and Development Authority (BARDA).
EscharEx®, our next-generation bioactive topical therapeutic under development in the U.S. for debridement of chronic and hard to heal wounds. In two Phase 2 studies, EscharEx was well-tolerated and has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds, within a few daily applications.
MW005, our topical biological drug for the treatment of non-melanoma skin cancers, is a clinical-stage product candidate under development.
Committed to innovation, we are dedicated to improving quality of care and patient lives. For more information, please visit www.mediwound.com.
Contacts:
| Boaz Gur-Lavie | Monique Kosse |
| Chief Financial Officer | Managing Director, LifeSci Advisors |
| MediWound Ltd. | 212-915-3820 |
| ir@mediwound.com | monique@lifesciadvisors.com |
FAQ
When will MediWound release its first quarter financial results for 2022?
What are the products being developed by MediWound?
What time is the conference call after MediWound's financial results announcement?
Is NexoBrid approved in the U.S.?
What support has MediWound received for NexoBrid?
